[1]高占群,李 霜,刘 杨.立普妥与瑞舒伐他汀联合缬沙坦治疗糖尿病 并发心力衰竭的临床疗效[J].医学信息,2019,32(15):140-142.[doi:10.3969/j.issn.1006-1959.2019.15.045]
　GAO Zhan-qun,LI Shuang,LIU Yang.Clinical Efficacy of Lipitor and Rosuvastatin Combined with Valsartan in the Treatment of Diabetes Complicated with Heart Failure[J].Journal of Medical Information,2019,32(15):140-142.[doi:10.3969/j.issn.1006-1959.2019.15.045]
点击复制

立普妥与瑞舒伐他汀联合缬沙坦治疗糖尿病 并发心力衰竭的临床疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年15期
页码:
140-142
栏目:
药物与临床
出版日期:
2019-08-01

文章信息/Info

Title:
Clinical Efficacy of Lipitor and Rosuvastatin Combined with Valsartan in the Treatment of Diabetes Complicated with Heart Failure
文章编号:
1006-1959（2019）15-0140-03
作者:
高占群; 李 霜; 刘 杨
佳木斯大学附属第一医院心内科，黑龙江 佳木斯 154002
Author(s):
GAO Zhan-qun; LI Shuang; LIU Yang
Department of Cardiology,the First Affiliated Hospital of Jiamusi University,Jiamusi154002,Heilongjiang,China
关键词:
糖尿病; 心力衰竭; 立普妥; 瑞舒伐他汀; 缬沙坦
Keywords:
Key words：Diabetes; Heart failure; Lipitor; Rosuvastatin; Valsartan
分类号:
R541.6
DOI:
10.3969/j.issn.1006-1959.2019.15.045
文献标志码:
A
摘要:
目的 分析立普妥与瑞舒伐他汀联合缬沙坦治疗糖尿病并发心力衰竭的临床疗效。方法 筛选2017年1月~2019年1月我院收治的2型糖尿病并发心力衰竭患者70例进行研究，采用随机数字表法均分为两组，每组35例。对照组给予瑞舒伐他汀联合缬沙坦治疗，观察组在对照组基础上加用立普妥治疗。治疗24周后分别检测两组患者糖化血红蛋白、甘油三酯、总胆固醇、低密度脂蛋白、高密度脂蛋白、左心室射血分数、血清hsCRP、血浆BNP等指标，评估患者心功能改善情况。结果 治疗后两组患者血脂、血糖水平均得到有效控制，观察组改善情况优于对照组，差异有统计学意义（P＜0.05）；患者血清hsCRP及血浆BNP指标与心功能分级呈正比，心功能分级越高，指标水平越高（r=0.822，P＜0.01）；患者血清hsCRP及血浆BNP指标与左室射血分数（LVEF）值呈反比，LVEF越低，指标水平越高（r=-0.731，P＜0.01）；治疗后LVEF、hsCRP、BNP组间比较，差异具有统计学意义（P＜0.05）；观察组治疗总有效率高于对照组，差异有统计学意义（P＜0.05）。结论 立普妥与瑞舒伐他汀联合缬沙坦治疗糖尿病并发心力衰竭患者效果显著，有利于控制血脂、血糖，积极改善心功能，临床有较高应用价值。
Abstract:
Abstract：Objective To analyze the clinical efficacy of Lipitor and rosuvastatin combined with valsartan in the treatment of diabetes complicated with heart failure.Methods A total of 70 patients with type 2 diabetes mellitus complicated with heart failure admitted to our hospital from January 2017 to January 2019 were enrolled. The randomized digital table method was divided into two groups, 35 cases in each group. The control group was treated with rosuvastatin and valsartan, and the observation group was treated with Lipitor on the basis of the control group. After 24 weeks of treatment, the glycosylated hemoglobin, triglyceride, total cholesterol, low density lipoprotein, high density lipoprotein, left ventricular ejection fraction, serum hsCRP, plasma BNP and other indicators were measured in the two groups to evaluate the improvement of cardiac function.Results After treatment, the blood lipids and blood glucose levels of the two groups were effectively controlled. The improvement of the observation group was better than that of the control group,the difference was statistically significant (P<0.05). The serum hsCRP and plasma BNP indexes were proportional to the cardiac function grading, and the cardiac function was observed. The higher the grade, the higher the index level (r=0.822, P<0.01). The serum hsCRP and plasma BNP levels were inversely proportional to the left ventricular ejection fraction (LVEF). The lower the LVEF, the higher the index level (r=-0.731,P<0.01); the difference between the LVEF, hsCRP and BNP groups after treatment was statistically significant (P<0.05). The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P<0.05).Conclusion Lipitor combined with rosuvastatin combined with valsartan is effective in the treatment of patients with diabetes mellitus complicated with heart failure. It is beneficial to control blood lipids, blood sugar, and positively improve heart function. It has high clinical value.

参考文献/References:

[1]刘正波,傅晶.氟伐他汀与缬沙坦联用对糖尿病肾病患者血脂及肾功能的影响[J].中西医结合心血管病电子杂志,2018,6(7):111-112. [2]刘亚玮,赵春艳,王春仙,等.舒洛地特与缬沙坦治疗Ⅲ期、Ⅳ期糖尿病肾病的临床疗效[J].现代生物医学进展,2017,17(19):74-77. [3]陈成华,王丽,张守来.缬沙坦联合阿托伐他汀对早期糖尿病肾病患者hs-CRP、LDL-C、SCr水平及肾功能的影响[J].医学临床研究,2018,35(1):65-67. [4]贾琼.小剂量瑞舒伐他汀对老年慢性心力衰竭合并心房颤动患者改善心功能及预防心房颤动复发的作用[J].中国医药指南,2018,16(7):49-50. [5]张菲菲.冠心病慢性心力衰竭患者应用不同剂量阿托伐他汀与瑞舒伐他汀的临床疗效对比及其安全性分析[J].药物生物技术,2018,25(2):62-65. [6]肖应东.瑞舒伐他汀钙联合缬沙坦治疗早期糖尿病肾病的临床分析[J].临床医药文献电子杂志,2017,4(57):11258-11259. [7]林文静,张秋霞,胡职舟.缬沙坦联合阿托伐他汀对早期糖尿病肾病患者微量白蛋白尿及血清hs-CRP水平的影响[J].中外医学研究,2017,15(11):134-135. [8]汪晓刚,陈德宣,李凯.缬沙坦联合阿托伐他汀对慢性心力衰竭患者心功能、心肌酶谱及甲状腺素水平的影响[J].海南医学院学报,2017,23(7):886-889. [9]夏杰,蔡春天.瑞舒伐他汀对糖尿病高胆固醇血症患者血脂及炎症因子的影响[J].海南医学院学报,2017,23(4):501-503. [10]刘宏,张秀峰,王静,等.阿托伐他汀和瑞舒伐他汀对糖尿病并创伤性蛛网膜下腔出血的疗效及对生活质量的影响比较[J].中国药业,2018,27,462(11):49-52. [11]陈熹,张柳婧,董远,等.阿托伐他汀与瑞舒伐他汀治疗2型糖尿病合并血脂代谢异常的疗效Meta分析[J].中国现代医生,2018,56(11):110-113,116. [12]胡媛媛,李莉,朱永锋.曲美他嗪联合瑞舒伐他汀治疗冠心病合并慢性心力衰竭的临床疗效[J].临床合理用药杂志,2017, 10(21):1-2. [13]朱珠,李欣宇.瑞舒伐他汀和阿托伐他汀对合并血脂异常的2型糖尿病患者的短期疗效及安全性比较[J].中国现代药物应用,2017,11(9):12-14.

相似文献/References:

[1]张西园.糖尿病与结直肠癌患者预后相关研究进展[J].医学信息,2018,31(01):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
　ZHANG Xi-yuan.Research Progress in the Relationship between Diabetes and the Prognosis of Colorectal Cancer[J].Journal of Medical Information,2018,31(15):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
[2]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
　GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Journal of Medical Information,2018,31(15):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[3]耿金萍.综合护理对甲状腺良性肿瘤并糖尿病患者手术效果的影响分析[J].医学信息,2018,31(01):163.[doi:10.3969/j.issn.1006-1959.2018.01.064]
　GENG Jin-ping.Analysis of the Effect of Comprehensive Nursing on the Surgical Effect of Thyroid Benign Tumor and Diabetic Patients[J].Journal of Medical Information,2018,31(15):163.[doi:10.3969/j.issn.1006-1959.2018.01.064]
[4]李雯婷,谈世华,余江明,等.踝肱指数检测在住院糖尿病患者中的重复性研究[J].医学信息,2018,31(03):159.[doi:10.3969/j.issn.1006-1959.2018.03.058]
　LI Wen-ting,TAN Shi-hua,YU Jiang-ming,et al.Study on Reproducibility of Ankle-brachial Index in Inpatients with Diabetes Mellitus[J].Journal of Medical Information,2018,31(15):159.[doi:10.3969/j.issn.1006-1959.2018.03.058]
[5]刘 静.冠状动脉粥样硬化性心脏病合并糖尿病的血脂检验结果分析[J].医学信息,2018,31(04):154.[doi:10.3969/j.issn.1006-1959.2018.04.057]
　LIU Jing.Analysis of Blood Lipid Test Results in Coronary Atherosclerotic Heart Disease Complicated with Diabetes Mellitus[J].Journal of Medical Information,2018,31(15):154.[doi:10.3969/j.issn.1006-1959.2018.04.057]
[6]谢勇丽,苏晓清,张雅薇.糖尿病痛性周围神经病变患者情绪调查分析[J].医学信息,2018,31(05):14.[doi:10.3969/j.issn.1006-1959.2018.05.005]
　XIE Yong-li,SU Xiao-qing,ZHANG Ya-wei.Investigation and Analysis of Mood in Patients with Diabetic Peripheral Neuropathy[J].Journal of Medical Information,2018,31(15):14.[doi:10.3969/j.issn.1006-1959.2018.05.005]
[7]张雅薇,朱明慧.首发为动眼神经麻痹的糖尿病合并动眼神经麻痹误诊为痛性眼肌麻痹1例分析[J].医学信息,2018,31(05):23.[doi:10.3969/j.issn.1006-1959.2018.05.008]
　ZHANG Ya-wei,ZHU Ming-hui.An Analysis of a Case of Diabetes Mellitus with Oculomotor Nerve Palsy Misdiagnosed as Painful Ophthalmoplegia[J].Journal of Medical Information,2018,31(15):23.[doi:10.3969/j.issn.1006-1959.2018.05.008]
[8]张宇宁.黄酮类化合物治疗糖尿病及其并发症的研究[J].医学信息,2018,31(05):50.[doi:10.3969/j.issn.1006-1959.2018.05.018]
　ZHANG Yu-ning.Study on Flavonoids in the Treatment of Diabetes Mellitus and its Complications[J].Journal of Medical Information,2018,31(15):50.[doi:10.3969/j.issn.1006-1959.2018.05.018]
[9]柳 梅.头孢哌酮钠舒巴坦钠治疗糖尿病并发尿路感染的 临床效果观察[J].医学信息,2018,31(07):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
　LIU Mei.Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium in Treatment of Diabetes Complicated with Urinary Tract Infection[J].Journal of Medical Information,2018,31(15):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
[10]吕桂英.影响糖尿病患者药物治疗依从性相关因素临床分析[J].医学信息,2018,31(08):109.[doi:10.3969/j.issn.1006-1959.2018.08.036]
　LV Gui-ying.Clinical Analysis of Factors Related to Compliance with Drug Therapy in Patients with Diabetes Mellitus[J].Journal of Medical Information,2018,31(15):109.[doi:10.3969/j.issn.1006-1959.2018.08.036]
[11]黄光明,赵兴昌,符显昭.水中运动联合中药内治对糖尿病大鼠心肌细胞凋亡和心功能的影响[J].医学信息,2022,35(11):72.[doi:10.3969/j.issn.1006-1959.2022.11.020]
　HUANG Guang-ming,ZHAO Xing-chang,FU Xian-zhao.Effects of Aquatic Therapeutic Exercise Combined with Traditional Chinese Medicine Internal Treatment on Cardiomyocyte Apoptosis and Cardiac Function in Diabetic Rats[J].Journal of Medical Information,2022,35(15):72.[doi:10.3969/j.issn.1006-1959.2022.11.020]

更新日期/Last Update: 2019-08-01